Oncology Conversation...

I was discharged from RCH at 11am this morning, and had a call with Dr. Noonan (Oncologist) this afternoon. She had just reviewed my file with all the latest, and before I even brought it up and she's going to:

1. Remove Keytruda from the trial altogether. If there is a chemo connection, that would be it. (She went to that explanation really quickly, which tells me there's something she knows that cardiology doesn't.)
2. Pause the treatments for a month. Restart in October.
3. I will get a CT next week, so we'll discuss the results before the treatments would restart.

So next steps are wait to see what the CT says. Then pivot. Like we always do.

PS: Alan found this NIH paper: "Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review". Keytruda (pembrolizumab) is a PD-1 checkpoint inhibitor. Notably,  Nivolumab is as well.